GlassScriptPhysician profile
Michael C Colotta
NPI 1477824340
$9,145.49
in general payments reported to CMS, 2019-2025
45 companies · $2,242 in 2025
The $2,242 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,779 · 2022: $1,585 · 2023: $1,749 · 2024: $1,791 · 2025: $2,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,781.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,281.41 | 2021-2025 | |
| Lilly USA, LLC | $1,256.63 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,159.77 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,147.43 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $624.44 | 2021-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $600.37 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.83 | 2021-2025 | Jardiance |
| Pfizer INC. | $280.49 | 2021-2025 | |
| Amarin Pharma, INC. | $264.04 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $263.76 | 2021-2024 | Xarelto |
| Glaxosmithkline, LLC. | $222.89 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Idorsia Pharmaceuticals US INC | $181.03 | 2022-2024 | Quviviq |
| Abbott Laboratories | $139.07 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Antares Pharma, INC. | $122.27 | 2021-2025 | Xyosted |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.52 | 2022-2025 | Caplyta |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Colotta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.